SGLT2 HYPE at a glance

Renown academic and non-academic partners

Envisaged recruiting sites

Countries all over Europe

Clinical Trials.gov Number:

NCT0680416

If you would like to learn more about the study plan and participation criteria click here.

Acronym

SGLT2 HYPE

Project title

SGLT2 inhibition for cardiovascular endpoint reduction in hypertension

Start Date

January 1st 2025

Project Duration

90 months

EU Contribution

€ 6 999 998.95

Grant Agreement Number

101156555

Coordinator

Universitätsklinikum
Schleswig-Holstein (UKSH) – Germany

Principal Investigator

Prof. Ingo Eitel

Coordinating Investigator

Dr. Elias Rawish

Clinical Project Management

Dr. Roza Saraei

Shaping the Future of Healthcare

Our Vision

To innovate hypertension treatment by introducing a new class of medication that improves heart and kidney health, ultimately reducing preventable illness, disability, and premature deaths on a global scale.

Our Mission

To lead pioneering research that establishes the effectiveness of SGLT2 inhibitors in hypertension management, influencing future treatment guidelines, improving patient outcomes, and driving transformative, life-saving advancements in healthcare.

The Trial

Analysis of protective benefits of Dapaglifozin

The SGLT2 HYPE trial is a large, international study evaluating the effects of dapagliflozin, an SGLT2 inhibitor, in elderly adults with uncontrolled hypertension at cardiovascular risk. This trial will monitor heart and kidney health outcomes in nearly 3,200 participants over a seven-year period, providing critical insights into the potential benefits of SGLT2 inhibitors for hypertension management.

Study Flowchart

After an initial eligibility check (Visit 1), participants are randomly assigned to receive either Dapagliflozin plus standard blood pressure medication or a placebo plus standard blood pressure medication (Visit 2). A safety visit follows (Visit 3), and participants then continue treatment with follow-up visits every six months until the trial concludes—currently expected by June 2032. During these visits, blood pressure measurements, laboratory sampling, and questionnaires are conducted to monitor participants’ health and treatment effects. The study ends with a final visit at the end of treatment.

Further information for patients

Further information for clinicians